TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB Share Price
Certificat
DE000CL7HDD0
| Market Closed - Bid/Ask 19:39:20 19/06/2024 BST | After market 20:17:16 | |||
| 3.08 EUR | -20.82% |
|
3.17 | +2.92% |
| Current month | -44.85% | ||
| 1 month | -54.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 3.08 | -20.82% |
| 18/06/24 | 3.89 | +4.01% |
| 17/06/24 | 3.74 | -10.53% |
| 14/06/24 | 4.18 | +4.76% |
| 13/06/24 | 3.99 | -6.78% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 07:39 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | CL7HDD |
| ISIN | DE000CL7HDD0 |
| Date issued | 07/04/2020 |
| Strike | 1,540 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.58 € |
|---|---|
| Lowest since issue | 3.08 € |
| Spread | 0.24 € |
| Spread % | 7.25% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,810
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.17%
- Stock Market
- Certificates
- Certificat